Abstracts
METHODS:
A historical case series sample of 591 patients diagnosed between 1993 and 1999, and treated in 12 practice sites with CHOP chemotherapy was used. Baseline anemia was defined as a hemoglobin (Hb) value Ͻ12 g/dl at baseline. Multiple logistic regression was used to determine factors associated with baseline anemia and model its relationship with response [no response (NR) versus partial response (PR) and complete response (CR)]. RESULTS: Anemia was present in 193/546 (35.3%) patients. Baseline Hb values were not available for 45 patients. Multiple logistic regression showed that baseline anemia was significantly associated with elevated LDH (OR; 95%CI) (OR ϭ 2.74; 1.66-4.50), presence of B symptoms (OR ϭ 2.16; 1.22-3.83), stage III-IV (OR ϭ 1.81: 1.10-2.93), male gender (0.42: 0.25-0.69), and large cell diffuse (OR ϭ 2.05; 1.19-3.54) or immunoblast (3.99; 1.78-9.02) histologic types. No significant interactions existed between any of the variables included in this model. Multiple logistic regression (predicting NR versus CR/PR) showed that the presence of baseline anemia (OR ϭ 2.29; 1.10-4.74) controlling for elevated LDH, advanced Stage III-IV, and age greater than or equal to 60, was a significant risk factor for NR to CHOP chemotherapy.
CONCLUSION:
The results support previous findings of the high prevalence of, and risk factors associated with, baseline anemia prior to CHOP chemotherapy. Baseline anemia was a significant risk factor for NR to CHOP chemotherapy, even after controlling for age, stage, and LDH. We conclude that additional studies with a comprehensive set of known risk factors validating this relationship between baseline anemia and response to CHOP chemotherapy are warranted. 
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COST OF TREATMENT AND FOLLOW UP OF BREAST CANCER. A RETROSPECTIVE EVALUATION IN A COMPREHENSIVE CANCER CENTRE
OBJECTIVE:
Breast cancer is one of the major causes of premature death for women. The management of its cost is important for both the national health insurance and the individual health-care providers. The objective of this study was to assess the global medical cost of breast cancer, from diagnosis to follow up, in a French medical centre. METHODS: Our evaluation was based on a retrospective cohort of 120 patients followed from January 1995 to February 2000 at Centre René Huguenin (SaintCloud). Comprehensive treatment schemes and clinical events were reported from patients' medical files. Detailed medical consumptions and mean duration of staff occupation were obtained primarily from direct observa-
